Anthrax Lethal Toxin Impairs CD1d-Mediated Antigen Presentation by Targeting the Extracellular Signal-Related Kinase 1/2 Mitogen-Activated Protein Kinase Pathway by Khan, Masood A. et al.
INFECTION AND IMMUNITY, May 2010, p. 1859–1863 Vol. 78, No. 5
0019-9567/10/$12.00 doi:10.1128/IAI.01307-09
Copyright © 2010, American Society for Microbiology. All Rights Reserved.
Anthrax Lethal Toxin Impairs CD1d-Mediated Antigen Presentation
by Targeting the Extracellular Signal-Related Kinase 1/2
Mitogen-Activated Protein Kinase Pathway
Masood A. Khan, Richard M. Gallo, and Randy R. Brutkiewicz*
Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana
Received 24 November 2009/Returned for modification 4 January 2010/Accepted 18 February 2010
Lethal toxin (LT) is a critical virulence factor of Bacillus anthracis and an important means by which this
bacterium evades the host’s immune system. In this study, we demonstrate that CD1d-expressing cells treated with
LT have reduced CD1d-mediated antigen presentation. We earlier showed an important role for the mitogen-
activated protein kinase extracellular signal-regulated kinase 1/2 (ERK1/2) in the regulation of CD1d-mediated
antigen presentation, and we report here that LT impairs antigen presentation by CD1d in an ERK1/2-dependent
manner. Similarly, LT and the ERK1/2 pathway-specific inhibitor U0126 caused a decrease in major histocompat-
ibility complex (MHC) class II-mediated antigen presentation. Confocal microscopy analyses revealed altered
intracellular distribution of CD1d and LAMP-1 in LT-treated cells, similar to the case for ERK1/2-inhibited cells.
These results suggest that Bacillus anthracis has the ability to evade the host’s innate immune system by reducing
CD1d-mediated antigen presentation through targeting the ERK1/2 pathway.
The Gram-positive bacterium Bacillus anthracis is the caus-
ative agent of anthrax and can kill its host after only a few days
(12, 14, 15, 23). Lethal toxin (LT), composed of lethal factor
(LF) and protective antigen (PA), is a major virulence factor
produced by this bacterium (5, 24). PA is involved in cell
binding, whereas LF possesses the enzymatic toxic activity (5,
8, 24). PA binds to cell surface receptors called anthrax toxin
receptors (ATRs) and facilitates the entry of LF into the host
cell (1, 7). LF is a metalloprotease responsible for impairing
mitogen-activated protein kinase (MAPK) signaling (8).
The MAPK signaling pathways are mediated by three different
serine/threonine protein kinases: extracellular signal-regulated ki-
nase 1/2 (ERK1/2), p38, and c-Jun N-terminal kinase (JNK) (11,
28). Each of these signaling pathways plays an important role in
the innate and adaptive immune responses (13, 37). A number of
bacterial pathogens manipulate signaling pathways to affect the
immune system of the host (6).Bacillus anthracis via LT is capable
of disrupting MAPK signaling pathways that are important for
dendritic cell and macrophage function (2, 3, 32). These pathways
include those we have shown to regulate CD1d-mediated antigen
presentation (10, 20, 25, 34).
CD1d molecules are structurally similar to major histocom-
patibility complex (MHC) class I molecules, but their intracel-
lular trafficking is similar to that of MHC class II molecules (9,
36). MHC class I and class II molecules present peptide anti-
gens to T cells, whereas CD1d molecules present lipid antigens
to a unique subset of T cells called natural killer T (NKT) cells
(9). Various pathogens inhibit CD1d-mediated antigen presen-
tation in order to evade the host’s innate immune system by
altering cell signaling pathways (25, 34). Because NKT cells are
an important component of the innate immune system and act
as a bridge between innate and adaptive immune responses, we
analyzed the effect of LT on CD1d-mediated antigen presen-
tation. Our results suggest that LT impairs CD1d-mediated
antigen presentation in an ERK1/2-dependent manner.
MATERIALS AND METHODS
Mice. Female BALB/c and C3H/HeN mice were purchased from the Jackson
Laboratory (Bar Harbor, ME) and used at 6 to 8 weeks of age. All procedures
were approved by the Institutional Animal Care and Use Committee of the
Indiana University School of Medicine.
Cell lines and other reagents. Murine LMTK-CD1d1 and L-CD1-DR4 cells
and the mouse CD1d-specific NKT cell hybridomas DN32.D3 (type I), N37-1A12
(type II), and N38-2C12 (type I) were cultured as described previously (19). TA3
B lymphoma cells and 3A9 and 17.9 T cell hybridomas were used as previously
described (19). Purified and biotinylated monoclonal antibodies (MAb) specific
for murine interleukin-2 (IL-2) and gamma interferon (IFN-) were purchased
from BD Biosciences (San Diego, CA). Recombinant mouse IL-2, IFN-, gran-
ulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-4 were ob-
tained from PeproTech (Rocky Hill, NJ). Both the ERK1/2 inhibitor (U0126)
and ERK1/2-specific antibodies were obtained from Cell Signaling Technology,
Inc. (Beverly, MA). Recombinant anthrax protective antigen (PA) and lethal
factor (LF) were purchased from List Biological Laboratories, Inc. (Campbell,
CA). Chloroquine was purchased from Sigma-Aldrich (St. Louis, MO).
Generation of BMDCs. Bone marrow cells from BALB/c mice were cultured
in the presence of 10 ng/ml each of GM-CSF and IL-4 as previously described
(10). On day 7, the plates were gently flushed (three or four times) to remove the
loosely adherent cells, which were subsequently used in analyses as bone marrow-
derived dendritic cells (BMDCs). For MHC class II-mediated antigen presenta-
tion, BMDCs were generated from C3H/HeN mice and were grown for 6 days in
the presence of GM-CSF and IL-4. On day 6, BMDCs were treated with lipo-
polysaccharide (LPS) overnight and used to analyze MHC class II-mediated
antigen as described previously (19).
NKT cell coculture assays. LMTK-CD1d1 cells or BMDCs were treated with
various concentrations of LF (0.1, 0.5, and 1.0 g/ml) with or without a fixed
concentration of PA (1.0 g/ml) for 24 h. The cells were then washed, fixed, and
cocultured with the indicated NKT cell hybridomas, and IL-2 production was
measured as described previously (26). For fresh NKT cells, liver mononuclear
cells from BALB/c mice were harvested as previously described (10) and cocul-
tured with LT-treated BMDCs for 48 h. IFN- production by NKT cells was
measured by enzyme-linked immunosorbent assay (ELISA) (10). To analyze the
effect of chloroquine on LT-induced reduction of CD1d-mediated antigen pre-
sentation, LMTK-CD1d1 cells were treated with LT (PA [1 g/ml] plus LF [1
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g/ml]) in the presence (10 M) or absence of chloroquine for 24 h, fixed, and
cocultured with NKT cells as described above.
MHC class II antigen presentation assay. Murine B cell lymphoma TA3 cells
or C3H/HeN BMDCs were treated with PA (1 g/ml), LF (1 g/ml), LT (PA
plus LF), or various concentrations (0, 2.5, 5.0, 10, and 20 M) of U0126 in the
presence of 2 mg/ml hen egg lysozyme (HEL). The cells were then washed, fixed,
and cocultured with the 3A9 T cell hybridoma to measure IL-2 production as
described previously (19). Similarly, L-CD1d1-DR4 cells were treated with LT or
the ERK1/2 pathway inhibitor U0126 in the presence of 10 M human serum
albumin (HSA). The cells were then washed, fixed, and cocultured with the 17.9
T cell hybridoma as described previously (19).
Western blotting. LMTK-CD1d1 cells were treated with vehicle or the indicated
concentrations of PA, LF, or LT (PA plus LF). The cells were lysed in lysis buffer
containing Complete protease inhibitor tablets (Roche Diagnostics, Indianapolis,
IN) as described previously (20). Equal amounts of protein were loaded into each
well, resolved on a 10% SDS-polyacrylamide gel, and subsequently transferred to a
polyvinylidene difluoride membrane (Millipore, Bedford, MA). Antibodies specific
for the indicated proteins were used to detect the respective bands, which were
developed by chemiluminescence before exposure on film (25).
Confocal microscopy. LMTK-CD1d1 cells plated in collagen-coated sterile
glass-bottom 35-mm dishes (MatTek, Ashland, MA) were treated with the indi-
cated concentrations of LT or U0126 for 24 h at 37°C. The cells were stained for
CD1d and LAMP-1, followed by fluorescein isothiocyanate (FITC)- and Texas
red-conjugated secondary antibodies, for analysis by confocal microscopy as
previously described (26, 29). The percent colocalization of CD1d and LAMP-1
was determined using MetaMorph software (version 5; Molecular Devices,
Sunnyvale, CA), in which six random fields were chosen from each picture.
Statistical analysis. The data were analyzed by a one-way analysis of variance
(ANOVA) with a Bonferroni posttest using GraphPad PRISM software (version
5.0 for Windows; GraphPad, San Diego, CA). A P value of below 0.05 was
considered significant. All experiments were performed three to five times.
RESULTS AND DISCUSSION
Anthrax lethal toxin impairs CD1d-mediated antigen pre-
sentation by inhibiting ERK1/2. In order to analyze the effect
of LT on CD1d-mediated antigen presentation, murine
LMTK-CD1d1 cells were treated with various concentrations
of LF with or without a fixed concentration of PA (1 g/ml)
and cocultured with NKT cells. LMTK-CD1d1 cells treated
with LT (PA plus LF) showed a concentration-dependent re-
duction in CD1d-mediated antigen presentation to either type
I (e.g., DN32.D3) or type II (e.g., N37-1A12) NKT cells, as
determined by decreased IL-2 production by the CD1d-specific
NKT cells (Fig. 1A). To determine the effect of LT on CD1d-
mediated antigen presentation by primary antigen-presenting
FIG. 1. Anthrax lethal toxin inhibits CD1d-mediated antigen presentation in an ERK/12-dependent manner. (A and B) LMTK-CD1d1 cells
(A) or BMDCs (B) were treated with vehicle, PA, LF, or LT as indicated, washed, fixed, and cocultured with the indicated NKT cell hybridomas.
IL-2 production was measured by ELISA. *, P  0.001 compared to vehicle. (C) BMDCs were treated with vehicle or LT for 24 h, washed, fixed,
and cocultured with primary NKT cells for 48 h. Supernatants were harvested to measure IFN-. *, P  0.001 compared to vehicle treatment.
(D) LMTK-CD1d1 cells were treated with vehicle or LT as described above, and the levels of phospho- and total ERK1/2 were analyzed by
Western blotting. Lanes: 1, vehicle; 2, PA (1 g/ml); 3, LF (1 g/ml); 4, PA (1 g/ml) plus LF (0.1 g/ml); 5, PA (1 g/ml) plus LF (0.5 g/ml);
6, PA (1 g/ml) plus LF (0.5 g/ml). *, P  0.001 compared to vehicle. (E) LMTK-CD1d1 cells were treated with vehicle or the ERK1/2
pathway-specific inhibitor U0126 (1, 2, 5, 10, or 20 M) for 24 h, washed, fixed, and cocultured with the indicated NKT cell hybridomas. *, P 
0.001 compared to vehicle. Error bars indicate standard deviations.
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cells, BMDCs were treated with LT as described above. As
found with LMTK-CD1d1 cells, LT also caused a reduction in
CD1d-mediated antigen presentation by BMDCs (Fig. 1B). LT
did not alter the cell surface expression of CD1d on either
LMTK-CD1d1 cells or BMDCs (data not shown). Prior studies
have shown that LT can be toxic to GM-CSF-induced BMDCs
under various conditions (2, 4). In all experiments performed
for this study, our BMDCs were generated using GM-CSF plus
IL-4, thus likely accounting for the high cell viability observed
at 24 h after LT-treatment (data not shown). BMDCs treated
with LT were also cocultured with primary NKT cells. LT
caused a reduction in CD1d-mediated antigen presentation to
primary NKT cells as well (Fig. 1C). These results suggest that
B. anthracis evades the innate immune system by impairing
CD1d-mediated antigen presentation.
We have shown that the ERK1/2 MAPK pathway plays an
important role in the regulation of CD1d-mediated antigen
presentation (25). Further, it has been reported that LT im-
pairs MAPK signaling (32). Thus, it was possible that the
reduction in antigen presentation following LT treatment was
due to changes in ERK1/2 activation. To test this, LMTK-
CD1d1 cells were exposed to vehicle or LT, and the status of
ERK1/2 phosphorylation was analyzed. LT substantially re-
duced ERK1/2 phosphorylation (Fig. 1D). Consistent with our
prior report (25), LMTK-CD1d1 cells treated with various
concentrations of the ERK1/2 pathway-specific inhibitor
U0126 were impaired in CD1d-mediated antigen presentation
(Fig. 1E). Interestingly, MAPKs play an important role in
T-cell receptor (TCR)-mediated signaling for optimum T cell
activation (37), and anthrax toxin causes functional anergy in
NKT cells by disrupting TCR signaling (17). MAPKs also reg-
ulate CD1d-mediated antigen presentation by altering the in-
tracellular trafficking and distribution of CD1d (25). As previ-
ously reported for other systems (2, 32), it was found that
treatment of LMTK-CD1d1 cells with LT caused a reduction
in ERK1/2 phosphorylation (Fig. 1D). The inhibitory effect of
LT on both CD1d-mediated antigen presentation and ERK1/2
phosphorylation is consistent with our earlier finding that
blocking the ERK1/2 pathway reduces CD1d-mediated antigen
presentation (25). This suggests that LT has the ability to affect
the innate immune system by reducing CD1d-mediated anti-
gen presentation through targeting ERK1/2.
LT impairs MHC class II-mediated antigen presentation. It
has been previously reported that LT-treated dendritic cells
were impaired in the priming of MHC class II-restricted anti-
gen-specific CD4 T cells and in the expression of costimula-
tory molecules such as CD40, CD80, and CD86 (2). MHC class
II molecules traverse through some of the same endocytic
compartments as CD1d (18, 26). Because LT reduced CD1d-
mediated antigen presentation, it was likely that antigen pre-
sentation by MHC class II would be altered as well. Therefore,
to analyze the effect of LT on MHC class II-mediated antigen
presentation, mouse TA3 B cell lymphoma cells were treated
with LT in the presence of hen egg lysozyme (HEL) and
cocultured with the 3A9 T cell hybridoma (19). As observed
with CD1d-mediated antigen presentation, LT treatment also
reduced antigen presentation by MHC class II molecules with-
out altering its cell surface expression (Fig. 2A and data not
shown). However, unlike what was observed with CD1d, LF
alone was able to significantly decrease MHC class II-mediated
antigen presentation. In another experiment, HLA-DR4-ex-
pressing L-CD1d1 (L-CD1-DR4) cells were treated with LT to
test presentation of human serum albumin (HSA) to the 17.9
T cell hybridoma. LT also impaired MHC class II-mediated
antigen presentation in this system (Fig. 2B). To analyze the
effect of LT on MHC class II-mediated antigen presentation by
primary cells, BMDCs from C3H/HeN mice were treated with
or without LT in the presence of HEL and cocultured with the
3A9 T cell hybridoma as previously described (19). Similar to
its effect on TA3 cells, LT also reduced MHC class II-mediated
antigen presentation by BMDCs (Fig. 2C). This suggests that
the functional expression of both CD1d and MHC class II
molecules is altered by LT and confirms a previous study an-
alyzing the latter antigen presentation system (2). These data
are also consistent with our prior reports suggesting that MHC
class II- and CD1d-mediated antigen presentations are simi-
larly regulated by specific cell signaling pathways (10, 19, 20).
Inhibition of the ERK1/2 pathway reduces MHC class II-
mediated antigen presentation. ERK1/2 has also been shown
to regulate intracellular trafficking, and its inhibition causes
intracellular accumulation of endosomal cargo (27). Endoso-
mal localization of the MEK1-ERK pathway is required for full
activation of ERK1/2, and disruption of the endosomal ERK
signaling results in aberrant subcellular distribution and traf-
ficking of late endosomes (31, 33). We have earlier shown that
inhibition of ERK1/2 reduces CD1d-mediated antigen presen-
tation by altering the intracellular distribution of CD1d (25).
ERK1/2 has been shown to regulate the class II activator
FIG. 2. Anthrax lethal toxin impairs MHC class II-mediated antigen presentation. (A) TA3 cells were treated with vehicle or LT in the presence
of HEL, fixed, and cocultured with the 3A9 T cell hybridoma. *, P  0.001 compared to vehicle. (B) L-CD1d1-DR4 cells were treated with vehicle
or LT in the presence of HSA, fixed, and then cocultured with the 17.9 T cell hybridoma. *, P  0.001 compared to vehicle. (C) BMDCs from
C3H/HeN mice were treated with vehicle, PA, LF, or LT in the presence of HEL; fixed; and cocultured as described above. The amount of IL-2
in the supernatant was measured by ELISA. *, P  0.001 compared to vehicle. Error bars indicate standard deviations.
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CIITA (33). To analyze the effect of ERK1/2 inhibition on
MHC class II-mediated antigen presentation, TA3 cells were
treated with various concentrations of U0126 in the presence
of HEL and cocultured with the 3A9 T cell hybridoma as
described earlier (19). Inhibition of the ERK1/2 pathway by
U0126 caused a concentration-dependent reduction in antigen
presentation by MHC class II molecules (Fig. 3A). In another
experiment, L-CD1-DR4 cells were treated with U0126 in the
presence of HSA and cocultured with the 17.9 T cell hybrid-
oma as described previously (19). U0126 also impaired MHC
class II-mediated antigen presentation by L-CD1-DR4 cells
(Fig. 3B). To analyze the effect of U0126 on primary antigen-
presenting cells, C3H/HeN BMDCs were treated with various
concentrations of U0126 in the presence or absence of HEL
and cocultured with the 3A9 T cell hybridoma. U0126 also
caused inhibition of MHC class II-mediated antigen presenta-
tion by BMDCs in a concentration-dependent manner (Fig.
3C). This suggests that the ERK1/2 signaling pathway regulates
the function of MHC class II molecules.
Anthrax lethal toxin alters the intracellular localization of
CD1d. CD1d molecules are likely loaded in late endocytic
compartments (26), and we have shown that inhibiting the
ERK1/2 pathway changes the intracellular distribution of
CD1d in these compartments (25). Thus, as LT inhibited the
phosphorylation of ERK1/2 and caused a reduction in CD1d-
mediated antigen presentation without a change in CD1d cell
surface levels, this effect might have been due to intracellular
changes in CD1d distribution. To determine if LT could in-
deed change the intracellular location of CD1d, LMTK-
CD1d1 cells were treated with or without LT and then the
colocalization of CD1d with the late endosome/lysosome
marker LAMP-1 was analyzed by confocal microscopy. U0126
served as a control, as we have already shown that inhibiting
the ERK1/2 pathway decreases the colocalization of CD1d and
LAMP-1 (25). A significant decrease in the colocalization of
CD1d and LAMP-1 was observed in cells treated with LT (i.e.,
PA plus LF) (Fig. 4A and B). These data are consistent with
FIG. 4. Treatment with LT alters the intracellular localization of CD1d. LMTK-CD1d1 cells were treated with vehicle, PA (1 g/ml), LF (1
g/ml), LT (PA plus LF at 1 g/ml each), or U0126 (10 M) as described in the legend to Fig. 1. The cells were then washed, fixed, stained for
CD1d (green) and LAMP-1 (red), and analyzed by confocal microscopy (A), and six random fields were chosen to calculate the percent
colocalization (B). *, P  0.001 compared to vehicle alone. Error bars indicate standard deviations.
FIG. 3. Inhibition of ERK1/2 impairs MHC class II-mediated antigen presentation. (A) TA3 cells were treated with vehicle or the indicated
concentrations of U0126 in the presence of HEL, fixed, and cocultured with the 3A9 T cell hybridoma. *, P  0.001 compared to vehicle.
(B) L-CD1d1-DR4 cells were treated with vehicle or the indicated concentrations of U0126 in the presence of HSA, fixed, and then cocultured
with the 17.9 T cell hybridoma. *, P  0.001 compared to vehicle. (C) BMDCs from C3H mice were treated with vehicle or the indicated
concentrations of U0126 in the presence of HEL, fixed, and cocultured as described above. The amount of IL-2 in the supernatant was measured
by ELISA. *, P  0.001 compared to vehicle. Error bars indicate standard deviations.
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the hypothesis that LT and U0126 impair antigen presentation
by CD1d by altering its intracellular distribution.
Various pathogens use the endocytic pathway for entry into
the host cells, and anthrax toxin requires the acidic pH in
endocytic compartments for its enzymatic activity (16). Thus,
not surprisingly, we found that chloroquine reduces the activity
of lethal toxin by preventing endosomal acidification and
thereby reverses its effect on CD1d-mediated antigen presen-
tation (data not shown). During an anthrax infection, would it
be possible that bacterial lipids are being presented by CD1d?
We and others have shown that lipids derived from Sphingo-
monas can stimulate NKT cells in a CD1d-dependent manner
(21, 22, 30, 35). Perhaps in the anthrax case, were this to be
true, the lipids might instead be inhibitory. Because endocytic
compartments are required for the processing and loading of
ligands onto CD1d (9), the inhibition of ERK1/2 may play an
important role in altering the distribution of CD1d molecules
in these intracellular compartments. An anthrax infection
could thus reduce lipid antigen loading of CD1d in those com-
partments by affecting intracellular trafficking as a result of
ERK1/2 inhibition by LT. This is supported by our prior report
showing impaired CD1d-mediated antigen presentation in
cells with reduced ERK1/2 activation (25). Therefore, these
results suggest that ERK1/2 plays a critical role in the endo-
somal trafficking of CD1d molecules, allowing these molecules
to be loaded with the proper ligands to activate NKT cells.
Overall, the results reported here strongly suggest that the
anthrax lethal toxin targets this signaling pathway as a means to
impair antigen presentation by CD1d in the mouse model.
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